Altimmune, Inc. (ALT)

Altimmune Statistics

Total Valuation

Altimmune has a market cap or net worth of $479.02 million. The enterprise value is $315.97 million.

Market Cap	479.02M
Enterprise Value	315.97M

Important Dates

The next estimated earnings date is Tuesday, November 12, 2024, before market open.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Altimmune has 71.07 million shares outstanding. The number of shares has increased by 26.80% in one year.

Shares Outstanding	71.07M
Shares Change (YoY)	+26.80%
Shares Change (QoQ)	+0.17%
Owned by Insiders (%)	0.74%
Owned by Institutions (%)	59.68%
Float	70.54M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.14
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	772.55
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.30, with a Debt / Equity ratio of 0.01.

Current Ratio	11.30
Quick Ratio	11.08
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2,947.97

Financial Efficiency

Return on equity (ROE) is -63.29% and return on invested capital (ROIC) is -37.65%.

Return on Equity (ROE)	-63.29%
Return on Assets (ROA)	-34.09%
Return on Capital (ROIC)	-37.65%
Revenue Per Employee	$6,932
Profits Per Employee	-$1.72M
Employee Count	59
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +176.78% in the last 52 weeks. The beta is 0.06, so Altimmune's price volatility has been lower than the market average.

Beta (5Y)	0.06
52-Week Price Change	+176.78%
50-Day Moving Average	6.76
200-Day Moving Average	7.74
Relative Strength Index (RSI)	47.69
Average Volume (20 Days)	1,659,378

Short Selling Information

The latest short interest is 22.23 million, so 31.28% of the outstanding shares have been sold short.

Short Interest	22.23M
Short Previous Month	22.40M
Short % of Shares Out	31.28%
Short % of Float	31.52%
Short Ratio (days to cover)	10.72

Income Statement

In the last 12 months, Altimmune had revenue of $409,000 and -$101.35 million in losses. Loss per share was -$1.60.

Revenue	409,000
Gross Profit	-77.53M
Operating Income	-97.28M
Pretax Income	-101.35M
Net Income	-101.35M
EBITDA	-96.89M
EBIT	-97.28M
Loss Per Share	-$1.60

Balance Sheet

The company has $164.91 million in cash and $1.86 million in debt, giving a net cash position of $163.05 million or $2.29 per share.

Cash & Cash Equivalents	164.91M
Total Debt	1.86M
Net Cash	163.05M
Net Cash Per Share	$2.29
Equity (Book Value)	152.53M
Book Value Per Share	2.15
Working Capital	156.03M

Cash Flow

Operating Cash Flow	-71.49M
Capital Expenditures	n/a
Free Cash Flow	-71.49M
FCF Per Share	-$1.01

Margins

Gross Margin	n/a
Operating Margin	-23,785.57%
Pretax Margin	-24,778.97%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-17,478.00%

Dividends & Yields

Altimmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-26.80%
Shareholder Yield	-26.80%
Earnings Yield	-21.16%
FCF Yield	-14.92%

Analyst Forecast

The average price target for Altimmune is $18.80, which is 178.93% higher than the current price. The consensus rating is "Buy".

Price Target	$18.80
Price Target Difference	178.93%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	290.58%
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on September 14, 2018. It was a reverse split with a ratio of 0.0333333:1.

Last Split Date	Sep 14, 2018
Split Type	Reverse
Split Ratio	0.0333333:1

Scores

Altimmune has an Altman Z-Score of 5.44 and a Piotroski F-Score of 1.

Altman Z-Score	5.44
Piotroski F-Score	1